---
title: "Alirocumab - Hypercholesterolemia"
sidebar: mydoc_sidebar
permalink: db09302-mesh-d006937-1.html
toc: false 
---


Path ID: `DB09302_MESH_D006937_1`
{% include image.html url="images/db09302-mesh-d006937-1.png" file="db09302-mesh-d006937-1.png" alt="db09302-mesh-d006937-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:C571059">MESH:C571059 </a> | alirocumab | Drug |
| <a href="https://identifiers.org/UniProt:Q8NBP7">UniProt:Q8NBP7 </a> | Proprotein convertase subtilisin/kexin type 9 | Protein |
| <a href="https://identifiers.org/GO:0090118">GO:0090118 </a> | receptor-mediated endocytosis involved in cholesterol transport | BiologicalProcess |
| <a href="https://identifiers.org/HP:0003141">HP:0003141 </a> | Increased LDL cholesterol concentration | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D006937">MESH:D006937 </a> | Hypercholesterolemia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Alirocumab | DECREASES ACTIVITY OF | Proprotein Convertase Subtilisin/Kexin Type 9 |
| Proprotein Convertase Subtilisin/Kexin Type 9 | NEGATIVELY REGULATES | Receptor-Mediated Endocytosis Involved In Cholesterol Transport |
| Receptor-Mediated Endocytosis Involved In Cholesterol Transport | NEGATIVELY CORRELATED WITH | Increased Ldl Cholesterol Concentration |
| Increased Ldl Cholesterol Concentration | MANIFESTATION OF | Hypercholesterolemia |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB09302](https://go.drugbank.com/drugs/DB09302)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109540/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109540/)
  - [https://en.wikipedia.org/wiki/Alirocumab#Pharmacology](https://en.wikipedia.org/wiki/Alirocumab#Pharmacology)
